Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Supportive Care in Cancer
Published in: Supportive Care in Cancer 8/2010

01-08-2010 | Editorial

Systematic reviews and guidelines for oral complications of cancer therapies: current challenges and future opportunities

Authors: Michael T. Brennan, Fred K. L. Spijkervet, Linda S. Elting

Published in: Supportive Care in Cancer | Issue 8/2010

Login to get access

Excerpt

The annual incidence of cancer in the world is estimated at more than 11 million cases with at least 1.3 million in the United States of America [1, 2]. Earlier cancer detection and advances in cancer therapies have provided important management advances to improve survival and quality of life. Common cancer treatment strategies include surgical resection, chemotherapy, radiotherapy, and hematopoietic stem cell transplantation. The goal of such treatments is to cure the patient from the cancer. However, side effects from these therapies can limit the effectiveness of treatment and have a marked impact on the patient’s quality of life both during and after completion of the cancer therapy. The oral cavity is a common site of complications related to cancer therapies. The Surgeon General’s report on Oral Health in America estimates that more than 30–35% (400,000 annually) of patients undergoing cancer treatment will develop oral complications [3]. …
Literature
1.
U.S. Cancer Statistics Working Group. United States cancer statistics: 2001 incidence and mortality. Atlanta, GA: Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute (2004), pp 1–699
2.
3.
U.S. Department of Health and Human Services. Oral Health in America: A Report of the Surgeon General, Executive Summary (2000) Rockville. U.S. Department of Health and Human Services, National Institute of Dental and Craniofacial Research, National Institutes of Health, MD
4.
Sonis ST, Elting LS, Keefe D, Peterson DE, Schubert M, Hauer-Jensen M, Bekele BN, Raber-Durlacher J, Donnelly JP, Rubenstein EB, for the Mucositis Study Section of the Multinational Association of Supportive Care in Cancer and the International Society for Oral Oncology (2004) Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients. Cancer 100:1995–2025CrossRefPubMed
5.
Rubenstein EB, Peterson DE, Schubert M, Keefe D, McGuire D, Epstein J, Elting LS, Fox PC, Cooksley C, Sonis ST, for the Mucositis Study Section of the Multinational Association of Supportive Care in Cancer and the International Society for Oral Oncology (2004) Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis. Cancer 100:2026–2046CrossRefPubMed
6.
Spielberger R, Stiff P, Bensinger W, Gentile T, Weisdorf D, Kewalramani T, Shea T, Yanovich S, Hansen K, Noga S, McCarty J, LeMaistre CF, Sung EC, Blazar BR, Elhardt D, Chen M, Emmanouilides C (2004) Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med 351:2590–2598CrossRefPubMed
Metadata
Title
Systematic reviews and guidelines for oral complications of cancer therapies: current challenges and future opportunities
Authors
Michael T. Brennan
Fred K. L. Spijkervet
Linda S. Elting
Publication date
01-08-2010
Publisher
Springer-Verlag
Published in
Supportive Care in Cancer / Issue 8/2010
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-010-0855-4

Other articles of this Issue 8/2010

Supportive Care in Cancer 8/2010 Go to the issue

Review Article

A systematic review of dental disease in patients undergoing cancer therapy

Special Article

A systematic review of oral fungal infections in patients receiving cancer therapy

Events

Special Section: Oral Complications of Cancer Therapies

Original Article

Ranked importance of outcomes of first-line versus repeated chemotherapy among ovarian cancer patients

Review Article

Systematic reviews of oral complications from cancer therapies, Oral Care Study Group, MASCC/ISOO: methodology and quality of the literature

Letter to the Editor

Increased blood culture sensitivity in pediatric oncology patients: is it the peripheral culture or increased collected blood volume?
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits